102 related articles for article (PubMed ID: 7923100)
1. Immunotherapy in liver tumors: II. Intratumoral injection with activated tumor-infiltrating lymphocytes, intrasplenic administration of recombinant interleukin-2 and interferon alpha causes tumor regression and lysis.
Liu DL; Håkansson CH; Seifert J
Cancer Lett; 1994 Sep; 85(1):39-46. PubMed ID: 7923100
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in liver tumors: III. A new experimental model of metastatic liver tumors from colorectal carcinoma for cytokine therapy.
Liu DL; Radnell M; Svanberg K; Seifert J
Cancer Lett; 1995 Jan; 88(2):211-19. PubMed ID: 7874695
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in liver tumours: I. Combined administration of recombinant interleukin-2 (IL-2) and interferon-alpha through the subcutaneous transposed spleen prolongs the half-life of IL-2 in vivo and enhances antitumor effects.
Liu DL; Seifert J; Cwikiel W
Cancer Lett; 1994 Sep; 85(1):31-7. PubMed ID: 7923099
[TBL] [Abstract][Full Text] [Related]
4. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo.
Dubinett SM; Patrone L; Tobias J; Cochran AJ; Wen DR; McBride WH
Cancer Immunol Immunother; 1993; 36(3):156-62. PubMed ID: 8382559
[TBL] [Abstract][Full Text] [Related]
9. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
10. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
Pak AS; Ip G; Wright MA; Young MR
Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
[TBL] [Abstract][Full Text] [Related]
11. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes.
Saris SC; Spiess P; Lieberman DM; Lin S; Walbridge S; Oldfield EH
J Neurosurg; 1992 Mar; 76(3):513-9. PubMed ID: 1738033
[TBL] [Abstract][Full Text] [Related]
12. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
13. Cerebrovascular effects and tumor kinetics after a single intratumoral injection of human recombinant interleukin-2 alone or in combination with intravenous chemotherapy in a rat model of glioma.
Watts RG; Merchant RE
Neurosurgery; 1992 Jul; 31(1):89-98; discussion 98-9. PubMed ID: 1641114
[TBL] [Abstract][Full Text] [Related]
14. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report.
Möller P; Wittig B; Schadendorf D
Anticancer Res; 1998; 18(2B):1237-41. PubMed ID: 9615794
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
17. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice.
Itoh T; Sakata Y; Yoshida Y; Tsushima K; Suzuki H; Saitoh S; Tamura Y; Ogasawara H; Sugimoto N; Takemori H
Cancer Immunol Immunother; 1990; 32(2):88-94. PubMed ID: 2126986
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
20. [Improved therapeutic effect of sequential immunotherapy with cyclophosphamide, large doses of OK-432 and recombinant interleukin-2 in breast cancer patients with disseminated metastatic liver tumors].
Akimoto M; Nishihira T; Hirakawa H; Abe M; Ohuchi N; Mori S; Kumagai K
Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):64-74. PubMed ID: 2014029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
